However, the use of AhR agonists as anticancer agents against breast cancer may lead to the down-regulation of SLCOs, and, therefore, the combination with OATP/SLCO substrate drugs should be investigated thoroughly. The gene discussed is AHR; the disease is breast carcinoma.